Myeloid leukemia: are we getting better?

Hamerschlak, Nelson

doi:10.1016/j.bjhh.2014.11.006

Cited by 2 publications

(3 citation statements)

References 8 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In any case, for myeloablative HSCT outcomes in AML, the stage of the disease, early (CR1), intermediate (CR2 or beyond), and advanced (relapsed or refractory) still is a strong predictor for survival. The Brazilian centers that report to CIBMTR have overall very similar outcomes, as AML treatment results are getting better in the country . However, it is important to point out that HSCT is not recommended to all cases of AML in CR1.…”

Section: Results Of Hematopoietic Stem Cell Transplantation For Acutementioning

confidence: 99%

“…As for remission induction, the classical 3 + 7 can lead to a 60% of CR. RFS, however, is short (5–10 months), and only 10% of these patients are alive after 2 yr . For fragile elderly patients or secondary AML, the utilization of hypomethylating agents such as decitabine or azacytidine can be considered as about 40% of the patients can achieve CR although it should be pointed out that RFS is also short, and not a curative approach.…”

Section: Hsct In Acute Myeloid Leukemia Of the Elderlymentioning

confidence: 99%

See 1 more Smart Citation

Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia

Silla

Dulley²,

Saboya³

et al. 2016

European J of Haematology

Self Cite

View full text Add to dashboard Cite

(i) Allo-HSCT is recommended for high-risk AML (IA); (ii) allo-HSCT is recommended for AML of intermediate risk (IA); (iii) allo-HSCT is recommended for AML relapsed/refractory (C4); (iv) auto-HSCT is recommended for AML after 1 consolidation (C4); (v) auto-HSCT is recommended for AML in CR1 (higher than QT in the Brazilian experience) (C4); (vi) auto-HSCT is accepted for AML M3 in second molecular complete remission (2B); (vii) peripheral blood instead of Bone Marrow HSC for advanced disease (2A); (viii) recommended conditioning protocols: Bu-Cy/Bu-Mel, Bu-Flu, TBI-Cy. In umbilical cord HSCT, consider ATG-based protocols (2A); (ix) allogeneic HSCT for the treatment of AML can be used in patients between 60 and 80 yr with good performance status and the absence of significant comorbidities (C4).

show abstract

Section: Results Of Hematopoietic Stem Cell Transplantation For Acutementioning

confidence: 99%

Section: Hsct In Acute Myeloid Leukemia Of the Elderlymentioning

confidence: 99%

Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia

Silla

Dulley²,

Saboya³

et al. 2016

European J of Haematology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Primary and secondary prevention strategies have provided increased survival rates for patients suffering from myeloid leukemia. 5 Both incidence and mortality rates are difficult to interpret because leukemia is often diagnosed incidentally or while evaluating other conditions. Therefore, differences in medical care may be a substantial bias in respect to incidence data.…”

mentioning

confidence: 99%